GUCY2C Vaccine for Colorectal and Small Bowel Cancer

This trial tests a new vaccine treatment for individuals with advanced colorectal or small bowel cancer that hasn't responded to standard treatments. The study administers two types of vaccines in a specific sequence to evaluate their safety and potential effectiveness. Participants will receive varying doses to determine the safest and most effective amount. The trial seeks individuals diagnosed with advanced colorectal or small bowel cancer who have not benefited from standard therapies. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial does not specify if you need to stop taking your current medications. However, you cannot use systemic steroids or immunosuppressive drugs, except for certain exceptions like low-dose adrenal replacement or brief courses for non-autoimmune conditions.

Research has shown that the GUCY2C Prime-Boost Vaccination is under study for safety in people with advanced cancers. In previous studies, two main vaccines were used: Ad5.F35-hGUCY2C-PADRE and Lm-GUCY2C. These studies aim to determine the safest dose levels and monitor any side effects after treatment.

Earlier research reported that the adenoviral vaccine Ad5.F35-hGUCY2C-PADRE was generally safe. Another trial used the Listeria-based vaccine, Lm-GUCY2C, to deliver a cancer antigen, a substance that triggers an immune response. This method has been tested to assess if it can safely help the immune system fight cancer cells.

Researchers are excited about the GUCY2C Prime-Boost Vaccination because it targets colorectal and small bowel cancer in a novel way. Unlike traditional treatments like chemotherapy and radiation, which can affect healthy cells, this vaccine leverages the body's immune system to specifically attack cancer cells by targeting GUCY2C, a biomarker present on these cancer cells. The treatment involves a two-step vaccine approach: an initial intramuscular injection followed by an intravenous boost, which potentially enhances the immune response. This method could offer a more precise, less toxic alternative to conventional therapies, potentially improving outcomes and quality of life for patients.

Research has shown that the GUCY2C prime-boost vaccination strategy holds promise for treating colorectal and small bowel cancer. This trial will test different dose levels of the GUCY2C vaccine. Studies have found that this method effectively activates the immune system to attack cancer cells. Specifically, one study demonstrated that a combination of a modified virus and a Listeria-based vaccine safely and successfully triggered an immune response against cancer in previous patients. Evidence indicates that the GUCY2C vaccine can help reduce the spread of tumors that have metastasized. These findings suggest that the vaccine could be useful in treating advanced cancers that have not responded to other treatments.¹²³⁴⁶